ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.26
-0.22%
Dow Jones
40,003.59
0.34%
Gold vs US Dollar
2,413.935
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,223.17
0.21%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NexImmune Inc (NEXI)

  7. NexImmune Inc (NEXI) News

NexImmune (NEXI)

NexImmune Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NEXI
DateTimeSourceHeadlineSymbolCompany
15/05/202421:01Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:NEXINexImmune Inc
09/05/202417:39Business WireApprobation des résultats financiers du groupe au 31 mars 2024, poursuite de la croissance et de l’augmentation de la marge de BAIIA, lancement d’un programme de rachat d’actions de 500 millions €NASDAQ:NEXINexImmune Inc
09/05/202417:39Business WireKonzernabschluss zum 31. März 2024 verabschiedet, kontinuierliches Wachstum und Ausweitung der EBITDA-Marge, Aktienrückkaufprogramm in Höhe von 500 Millionen Euro gestartetNASDAQ:NEXINexImmune Inc
09/05/202407:00Business WireGroup Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, € 500 Million Share Buy-Back Program LaunchedNASDAQ:NEXINexImmune Inc
07/03/202418:20Business WireKonzernergebnis zum 31. Dezember 2023 genehmigt, starke Margenausweitung und Liquiditätsüberschuss von 601 Millionen Euro, Aktienrückkaufprogramm von 500 Millionen EuroNASDAQ:NEXINexImmune Inc
07/03/202417:33Business WireApprobation des résultats financiers du groupe au 31 décembre 2023 ; forte expansion de la marge et génération d'excédents de trésorerie à hauteur de 601 millions d’euros ; programme de rachat d’actions de 500 millions d’eurosNASDAQ:NEXINexImmune Inc
07/03/202406:31Business WireApprovati i risultati finanziari di Gruppo al 31 dicembre 2023, Forte espansione dell’EBITDA margin ed excess cash generation a € 601 milioni, € 500 milioni per acquisto di azioni proprieNASDAQ:NEXINexImmune Inc
07/03/202406:30Business WireGroup Financial Results as of December 31st 2023 Approved, Strong Margin Expansion and Excess Cash Generation at € 601 Million, € 500 Million Share Buy-Back ProgramNASDAQ:NEXINexImmune Inc
06/02/202421:42GlobeNewswire Inc.NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NEXINexImmune Inc
06/02/202421:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NEXINexImmune Inc
05/02/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
05/02/202421:34Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NEXINexImmune Inc
02/02/202419:00GlobeNewswire Inc.NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NEXINexImmune Inc
02/02/202418:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
01/02/202414:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
19/01/202421:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
18/01/202421:43Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NEXINexImmune Inc
22/12/202321:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
01/12/202318:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NEXINexImmune Inc
22/11/202322:40Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:NEXINexImmune Inc
22/11/202322:34Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:NEXINexImmune Inc
22/11/202322:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NEXINexImmune Inc
21/11/202321:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NEXINexImmune Inc
20/11/202322:19Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NEXINexImmune Inc
20/11/202322:01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:NEXINexImmune Inc
17/11/202321:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NEXINexImmune Inc
15/11/202321:17Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:NEXINexImmune Inc
09/11/202322:47Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:NEXINexImmune Inc
09/11/202314:35Business WireFinanzergebnisse der Gruppe zum 30. September 2023 bestätigen solide finanzielle Leistung im Rahmen des Plans und kontinuierliche Ausweitung der EBITDA-MargeNASDAQ:NEXINexImmune Inc
09/11/202313:52Business WireLes résultats financiers du groupe au 30 septembre 2023 ont été approuvés, croissance solide conforme au plan, avec une augmentation continue de la marge de BAIIANASDAQ:NEXINexImmune Inc
 Showing the most relevant articles for your search:NASDAQ:NEXI

Your Recent History

NYSE
TUP
Tupperware Brands
LSE
KF14
Citi Fun 25
LSE
BJ19
Citi Fun 26
USOTC
BENH
Bio En (CE)
COIN
TYMGBP
LSE
TBGR
LSE
AL31
Citi Fun 24
LSE
MER
Mears
NASDAQ
HELE
Helen of Troy
NYSE
EFC
Ellington Financial
AQSE
CRS.GB
Crystal Amber
NASDAQ
KRFT
LSE
0QNA
Basilea Pharmaceutica
LSE
SUR
Sureserve
BIT
UIB761
UniCredit Bank
BIT
ACE
Acea
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved